BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended December 31, 1998 (First Quarter of Fiscal Year 1999)

Business Overview: BD operates in two primary segments: Medical Supplies and Devices ("Medical") and Diagnostic Systems ("Diagnostic"). The company manufactures and distributes medical products, including infusion therapy, syringes, and diagnostic systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 10% year-over-year. Growth was driven by the Medical segment (+14%) and Diagnostic segment (+4%).
• Currency Impact: A stronger U.S. dollar reduced revenues by an estimated $4 million and diluted EPS by approximately one cent.
• Segment Performance:
  • Medical: International revenues surged 35% (37% excluding currency), driven by infusion therapy and prefillable syringes. Domestic Medical revenues declined 4% due to a decrease in diabetes health care business compared to a high-growth prior year period.
  • Diagnostic: International revenues grew 11% (12% excluding currency). Domestic revenues declined 1% due to cost containment in U.S. infectious disease testing.
• Expenses: Selling and administrative expenses rose to 29% of revenue (from 28.4%) due to acquisition-related costs and enterprise-wide business system upgrades. R&D spending increased 10% to $49 million.
• Tax Rate: The effective tax rate dropped to 19% from 29% in the prior year, largely due to a favorable $7 million tax judgment in Brazil.
• Cash Flow: Operating cash flow decreased significantly to $87 million from $164 million, attributed to inventory replenishment following a strong fourth quarter in the prior fiscal year.

Guidance, Outlook, and Risks

• Capital Expenditures: The company expects full-year capital expenditures to be approximately $225 million.
• Tax Outlook: Management expects a full-year reported tax rate of about 25%.
• Acquisitions: BD completed two acquisitions in the quarter for an aggregate purchase price of $42 million (net of cash acquired).
• Dividends: The Board increased the quarterly dividend to $0.085 per share from $0.0725.
• Year 2000 (Y2K) Readiness:
  • Total estimated cost for Y2K compliance is approximately $15 million; $4.5 million incurred to date.
  • Remediation and testing are ongoing, with completion targeted for mid-to-late 1999.
  • Risks include potential third-party claims and disruptions if compliance is not achieved, though management believes the plan is effective.
• Legal Proceedings: BD is a defendant in approximately 214 product liability lawsuits regarding natural rubber latex and 10 lawsuits regarding needle sticks. Management does not expect these to have a material impact on financial condition.
• Foreign Exchange: Significant depreciation of the Brazilian Real was hedged. The transition to the Euro is underway with no expected material impact.

Investor Verification Checklist

• Inventory Levels: Verify the impact of the inventory replenishment on future working capital needs and cash flow stability.
• Acquisition Integration: Assess the financial performance and integration status of the BOC Group Medical Devices Division and the two new Q1 acquisitions.
• Y2K Contingency: Monitor the progress of the Y2K remediation plan and any emerging third-party claims or costs exceeding the $15 million estimate.
• Legal Exposure: Track developments in the latex glove and needle stick litigation to ensure the "no material impact" assessment remains valid.
• Segment Mix: Evaluate the sustainability of the 35% growth in International Medical revenues versus the decline in Domestic Medical revenues.